The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

83563583534983383026322d45-e1ed-4540-ad8e-81fecc71ab7541be5706-ef4d-4b3f-9c5f-f0575056194051da36e2-8797-4bd7-9380-5a904f74a84eARGS_News_2015_6_16_General_Releases.pdfARGS_News_2015_6_15_General_Releases.pdfARGS_News_2015_6_4_General_Releases.pdf1456717049219251232015-6-16T16:30:0-4:02015-6-15T8:30:0-4:02015-6-4T8:30:0-4:0918252917906916491General ReleasesGeneral ReleasesGeneral ReleasesArgos Therapeutics to Host Conference Call With Principal Investigator Dr. Robert Figlin on Monday June 8, 2015 at 4:30pm EDTArgos Therapeutics to Present at the 2015 JMP Securities Life Sciences ConferenceArgos Therapeutics Hires John D. Menditto as Vice President of Corporate Communications and Investor RelationsIndependent Data Monitoring Committee Recommends Continuation of Pivotal ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma103103103201520152015No Error0

Argos Therapeutics to Present at the 2015 JMP Securities Life Sciences Conference
Read more

Argos Therapeutics Hires John D. Menditto as Vice President of Corporate Communications and Investor Relations
Read more

Independent Data Monitoring Committee Recommends Continuation of Pivotal ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC